Pembrolizumab alone and pembrolizumab plus chemotherapy in previously treated, extrapulmonary poorly differentiated neuroendocrine carcinomas.
Raj N, Chan JA, Wang SJ, Aggarwal RR, Calabrese S, DeMore A, Fong L, Grabowsky J, Hope TA, Kolli KP, Mulvey CK, Munster PN, Perez K, Punn S, Reidy-Lagunes D, Von Fedak S, Zhang L, Bergsland EK.
Raj N, et al. Among authors: grabowsky j.
Br J Cancer. 2023 Aug;129(2):291-300. doi: 10.1038/s41416-023-02298-8. Epub 2023 May 19.
Br J Cancer. 2023.
PMID: 37208512
Free PMC article.
Clinical Trial.